Description
This webinar focuses on the clinical aspects of HPV infections and the critical role of HPV vaccination in preventing cervical cancer. The session will cover HPV epidemiology, natural history of infection, and interpretation of screening results in routine practice. Experts will discuss current vaccine recommendations, efficacy, safety, and strategies to improve vaccine uptake across different age groups. Practical guidance on counseling patients, addressing myths, and integrating screening with vaccination will be shared. Designed for healthcare professionals, this webinar aims to strengthen evidence-based cervical cancer prevention efforts.
Summary Listen
- Cervical cancer prevention has dramatically improved in the last 20-25 years, primarily through HPV vaccination and screening programs. Cervical health is crucial for fertility, pregnancy, and cancer prevention, making early detection and preventative measures paramount.
- Key steps for cervical health involve starting Pap tests at age 21, combining HPV tests with Pap tests after age 30, and adhering to doctor-recommended screening schedules. These practices aim to identify abnormal cell changes early on.
- The human papillomavirus (HPV) is the primary cause of cervical cancer. While HPV infection is widespread, with studies showing a high prevalence even in women with normal cervical cytology, most infections resolve on their own. However, persistent infection with high-risk HPV types can lead to cervical cancer, making vaccination a crucial intervention.
- HPV types 16, 18, 45, 31, 33, 52, and 58 account for approximately 90% of HPV-related squamous cell carcinomas. HPV can also cause genital warts and cancers of the anus, oropharynx, vulva, vagina, and penis, highlighting the broad impact of HPV infection.
- HPV spreads through skin-to-skin contact and can be transferred through sexual intercourse. While most HPV infections are asymptomatic and resolve within 1-2 years, persistent infection can lead to cervical cancer after a long latency period (around 20 years).
- Currently, there's no specific treatment for HPV infection, but screening and treatment for pre-invasive cervical disease are highly effective in preventing progression to cervical cancer. HPV vaccines offer a touch of severe or touch of the protector, providing a highly successful means of preventing HPV-related cancers.
- Three prophylactic HPV vaccines are available: bivalent, quadrivalent, and nonavalent. All are intended to be administered before the onset of sexual activity, and they do not contain live biological products or viral DNA, making them non-infectious. The vaccines are indicated for use in females and males from the age of 9 years onwards.
- The bivalent vaccine targets HPV types 16 and 18, while the quadrivalent covers types 6, 11, 16, and 18. The nonavalent vaccine covers 9 HPV types. Immunoglobulin G antibodies produced by the vaccines provide long-term HPV-specific immunity, and the immunological response is much stronger than that from natural infection.
- In India, HPV vaccine schedules typically involve two doses for ages 9-14 and three doses for those 15-26 or older/immunocompromised, with the schedule completed within a year for best results. The two-dose schedule has been approved based on studies demonstrating non-inferior immunity compared to the three-dose regimen.
- HPV vaccines offer protection for up to 10 years, and current evidence suggests that all three licensed vaccines have similar effectiveness in preventing cervical cancer and genital warts. Data suggest that all the 3 licensed HPV vaccines have relatively similar effectiveness in preventing cervical cancer and non genital warts.
- HPV vaccines are generally considered safe, with common side effects including pain at the injection site. Systemic reactions like headache, dizziness, and nausea are also mild and treatable. While vaccination during pregnancy is not recommended, limited data indicate no specific safety concerns for fetal development if inadvertently administered.
- Key prevention strategies include regular screenings with Pap and HPV tests, starting at age 21, practicing safe sex, avoiding smoking, and maintaining a healthy diet. The HPV vaccine remains the most effective means of preventing cervical cancer and related conditions.
Sample Certificate
About the Speakers
.webp)
Dr. Pankaj Desai
Consultant Gynecologist, Janani Maternity Hospital, Vadodara, Gujarat
Comments
Comments
You must be logged in to leave a comment.